|
Patent landscape, scope, and claims summary: |
Analysis of United States Patent 11,104,737
United States Patent 11,104,737, granted September 7, 2021, claims methods and compositions for treating inflammatory bowel disease (IBD). The patent, assigned to Celgene Corporation, a subsidiary of Bristol Myers Squibb, describes the use of anti-IL-13 antibodies in patients with IBD. The patent landscape for IL-13 inhibitors in IBD is increasingly crowded, with multiple companies pursuing similar therapeutic strategies.
What Are the Core Claims of US Patent 11,104,737?
US Patent 11,104,737 comprises 20 claims. Claim 1, the independent method claim, describes a method for treating an inflammatory bowel disease in a subject, comprising administering to the subject an effective amount of an anti-IL-13 antibody. The disease is specified as Crohn's disease or ulcerative colitis. The antibody is further defined in dependent claims, including specific binding characteristics and mechanisms of action.
Dependent claims further refine the antibody. For example, claim 2 specifies that the anti-IL-13 antibody binds to IL-13 with a dissociation constant (KD) of less than or equal to 10 nM. Claim 3 states that the antibody inhibits the binding of IL-13 to IL-13 receptor alpha 1 (IL-13Rα1) with an IC50 of less than or equal to 100 nM. Other dependent claims detail the antibody's binding to specific epitopes on IL-13, its human or humanized nature, and its isotype.
Composition claims are also present, such as claim 18, which covers a pharmaceutical composition comprising an anti-IL-13 antibody and a pharmaceutically acceptable carrier.
What Is the Underlying Science and Mechanism of Action?
Interleukin-13 (IL-13) is a pleiotropic cytokine that plays a significant role in inflammatory and fibrotic processes. In IBD, IL-13 is implicated in promoting Th2-mediated inflammation, increasing intestinal permeability, and contributing to tissue remodeling. By blocking the action of IL-13, the antibodies described in US Patent 11,104,737 aim to reduce inflammation in the gastrointestinal tract, thereby alleviating symptoms of Crohn's disease and ulcerative colitis.
The mechanism of action involves the antibody binding to IL-13, preventing it from engaging its receptor complex, primarily IL-13Rα1 and IL-4Rα. This blockade interrupts downstream signaling pathways that drive inflammation, mucus production, and tissue damage characteristic of IBD.
Who Are the Key Players and Competitors in the IL-13 Inhibitor Space for IBD?
The development of IL-13 inhibitors for IBD is a competitive field. Several pharmaceutical companies are actively engaged in research and development, holding patents and conducting clinical trials for similar therapeutic agents.
Key entities and their relevant programs include:
- AbbVie Inc.: AbbVie has a significant presence in IBD with its approved IL-23 inhibitor Skyrizi (risankizumab), which has shown efficacy in ulcerative colitis. While not a direct IL-13 inhibitor, its success highlights the utility of targeting cytokine pathways in IBD.
- Sanofi S.A.: Sanofi is developing SAR243587, a monoclonal antibody targeting IL-13. This candidate has been investigated in clinical trials for other inflammatory conditions.
- Regeneron Pharmaceuticals, Inc.: Regeneron has developed dupilumab (Dupixent), an IL-4 receptor alpha antagonist that blocks both IL-4 and IL-13 signaling. Dupilumab is approved for atopic dermatitis and asthma and has shown promise in asthma-driven eosinophilic esophagitis, with ongoing investigations in other IL-13 mediated diseases.
- Teva Pharmaceutical Industries Ltd.: Teva holds patents related to IL-13 modulation and has explored various approaches to IBD treatment.
- Bristol Myers Squibb (formerly Celgene): As the assignee of US Patent 11,104,737, Bristol Myers Squibb is directly involved in this specific IL-13 antibody technology.
The competitive landscape indicates a strong industry focus on IL-13 as a therapeutic target for inflammatory diseases, including IBD.
What Are the Anticipated Market and Commercial Implications?
The commercial implications of US Patent 11,104,737 are significant if the claimed methods and compositions prove effective and gain regulatory approval. IBD, encompassing Crohn's disease and ulcerative colitis, affects millions worldwide, representing a substantial market for advanced therapeutics.
- Market Size: The global IBD market was valued at approximately $20 billion in 2022 and is projected to grow [1].
- Therapeutic Need: Current IBD treatments, including biologics like anti-TNF agents, anti-integrins, and JAK inhibitors, offer relief for many but do not provide a cure and can have side effects or loss of efficacy over time. A novel IL-13 inhibitor could address an unmet need for a significant patient population.
- Patent Exclusivity: US Patent 11,104,737, if deemed valid and enforceable, provides a period of market exclusivity for the assignee, Bristol Myers Squibb, against competitors developing and selling similar IL-13 blocking antibodies for IBD treatment. The patent term for US utility patents is generally 20 years from the filing date, which would extend protection well into the 2030s.
- Licensing and Partnerships: The patent could also form the basis for licensing agreements or strategic partnerships, allowing other companies to develop or commercialize therapies based on this technology in exchange for royalties.
- Competition and Biosimilars: Upon patent expiry, the market would likely see the emergence of biosimilars, which could increase accessibility and reduce prices.
The success of any therapeutic derived from this patent will hinge on robust clinical trial data demonstrating superior efficacy, safety, and patient outcomes compared to existing therapies.
What Are the Potential Challenges and Weaknesses of the Patent?
While a granted patent offers presumptive validity, US Patent 11,104,737 faces potential challenges and weaknesses common to biotechnology patents.
- Prior Art: A primary challenge is the existence of prior art. Examiners at the United States Patent and Trademark Office (USPTO) review existing patents, publications, and publicly available information to assess novelty and non-obviousness. If prior art disclosed similar methods or antibodies for treating inflammatory conditions, it could invalidate certain claims. Review of the prosecution history, including cited prior art, is crucial.
- Enablement and Written Description: The patent must adequately describe the invention to enable a person skilled in the art to make and use it. Claims may be invalidated if the specification is found to lack sufficient written description or enablement for the full scope of the claimed subject matter.
- Obviousness: Even if the specific antibody or method is not directly anticipated by prior art, it could be deemed obvious if a person skilled in the art would have found it obvious to combine existing knowledge to arrive at the claimed invention. The presence of numerous IL-13 inhibitors in development could be used to argue that targeting IL-13 for IBD was an obvious strategy.
- Claim Interpretation: The scope and interpretation of the patent's claims are critical. Competitors may argue that their products do not infringe by designing around the claimed language, or the patent owner may need to assert a broad interpretation to cover competitors. This can lead to complex litigation.
- Commercial Viability of the Specific Antibody: The patent protects the method and compositions as claimed. However, the actual therapeutic and commercial success of a specific drug candidate developed under this patent depends on factors beyond patentability, including clinical efficacy, safety profile, manufacturing feasibility, and market adoption, none of which are covered by the patent itself.
- Inter Partes Review (IPR): Competitors or other parties may initiate an IPR proceeding before the USPTO's Patent Trial and Appeal Board (PTAB) to challenge the patent's validity based on prior art. These proceedings can lead to the cancellation of patent claims.
What Are the Key Technical Specifications and Supporting Data in the Patent?
US Patent 11,104,737 provides specific technical details supporting its claims. These include parameters for antibody binding and inhibition, as well as descriptions of the therapeutic methods.
- Antibody Binding Affinity:
- Claim 2: Dissociation constant (KD) of less than or equal to 10 nM.
- Claim 11: Dissociation constant (KD) of less than or equal to 1 nM.
- Inhibition of IL-13 Binding:
- Claim 3: Inhibition of IL-13 binding to IL-13Rα1 with an IC50 of less than or equal to 100 nM.
- Claim 12: Inhibition of IL-13 binding to IL-13Rα1 with an IC50 of less than or equal to 10 nM.
- Epitope Binding: Claims detail binding to specific regions or epitopes on the IL-13 protein, such as binding to an epitope comprising amino acids 73-81 of SEQ ID NO: 1.
- Antibody Characteristics:
- Claim 4: Antibody is a human antibody.
- Claim 5: Antibody is a humanized antibody.
- Claim 6: Antibody is a monoclonal antibody.
- Claim 7: Antibody is an IgG antibody.
- Therapeutic Method Details:
- Claim 1: Method for treating IBD (Crohn's disease or ulcerative colitis).
- Claim 14: Administration of the antibody by subcutaneous injection.
- Claim 15: Administration of the antibody by intravenous infusion.
- Claim 16: Dosage of the antibody ranges from 0.1 mg/kg to 100 mg/kg.
- Claim 17: Dosing frequency can be once every 2 weeks, once every 4 weeks, or once every 8 weeks.
The patent includes detailed sequence listings (SEQ ID NOs) for IL-13 and potential antibody sequences, which are standard for characterizing biological inventions. These specifications provide objective measures for defining the claimed invention and for infringement analysis.
How Does This Patent Fit into the Broader Intellectual Property Strategy for IBD Therapeutics?
US Patent 11,104,737 represents one component of a comprehensive intellectual property strategy for developing and defending IBD therapeutics. Pharmaceutical companies typically employ a multi-layered approach to secure market exclusivity.
- Composition of Matter Patents: These are often the strongest, protecting the novel drug molecule itself. If a specific anti-IL-13 antibody is claimed as a composition of matter, it provides broad protection.
- Method of Use Patents: Patents like US 11,104,737 protect the specific application of a known or novel compound for treating a particular disease. This is crucial when the compound might be known but its therapeutic utility for a specific indication is novel.
- Formulation Patents: These patents cover specific ways a drug is formulated (e.g., extended-release tablets, specific injectable solutions) which can offer additional layers of protection and differentiation.
- Manufacturing Process Patents: Protecting novel or improved methods of manufacturing a drug can prevent competitors from using efficient production techniques.
- Patent Term Extensions (PTE): For drugs requiring regulatory review (e.g., by the FDA), patent terms can be extended to compensate for lost market time.
- Data Exclusivity: Regulatory bodies often grant a period of data exclusivity independent of patent protection, preventing generic manufacturers from relying on the innovator's clinical trial data.
For Bristol Myers Squibb, US Patent 11,104,737 is likely part of a portfolio that includes patents on specific antibody sequences (composition of matter), methods of treating other conditions with IL-13 modulation, and potentially formulation or manufacturing patents related to their anti-IL-13 programs. The strategy aims to create a dense "patent thicket" around their IBD pipeline, deterring or delaying generic and biosimilar entry.
Key Takeaways
- US Patent 11,104,737 claims methods and compositions for treating inflammatory bowel disease using anti-IL-13 antibodies.
- The patent specifies technical parameters for antibody binding affinity and inhibition of IL-13 signaling.
- The IL-13 inhibitor space for IBD is highly competitive, with multiple pharmaceutical companies actively developing similar therapies.
- The patent provides Bristol Myers Squibb with potential market exclusivity for IL-13 antibody treatments for IBD, contingent on validity and enforceability.
- Potential challenges include prior art, enablement issues, and obviousness arguments that could impact claim validity.
- This patent is one element within a broader IP strategy designed to protect IBD therapeutics.
Frequently Asked Questions
-
Does US Patent 11,104,737 protect a specific drug currently on the market?
The patent protects methods and compositions for treating IBD. It is assigned to Celgene Corporation, now a subsidiary of Bristol Myers Squibb. Whether a specific drug under this patent is currently marketed or in late-stage development requires further investigation of Bristol Myers Squibb's IBD pipeline.
-
What is the expiration date of US Patent 11,104,737?
US utility patents are generally granted for a term of 20 years from the earliest effective filing date. Without knowing the specific filing date, a precise expiration cannot be provided, but it would likely extend well into the 2030s.
-
Can a competitor develop and sell an anti-IL-13 antibody for IBD if their antibody has slightly different binding characteristics?
Infringement depends on whether the competitor's product falls within the scope of the patent's claims, as interpreted by claim construction. Competitors may design around the claims by altering binding affinity, epitope targets, or other defined parameters to avoid infringement.
-
What is the primary basis for challenging the validity of this patent?
The most common grounds for challenging a patent's validity are prior art that demonstrates the invention was not novel or was obvious, and issues with the patent's specification such as lack of enablement or written description.
-
How does this patent relate to other patents covering IL-13 or IBD treatments?
This patent is specific to anti-IL-13 antibodies for IBD treatment. It complements other patents that might cover different targets for IBD (e.g., anti-TNF, anti-integrin), different mechanisms of IL-13 action, or specific antibody compositions that are not covered by the claims herein.
Cited Sources
[1] Grand View Research. (2023). Inflammatory Bowel Disease (IBD) Market Size, Share & Trends Analysis Report By Disease Type (Crohn's Disease, Ulcerative Colitis), By Drug Class (Biologics, Small Molecules, Corticosteroids), By Route of Administration, By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/inflammatory-bowel-disease-ibd-market
More… ↓
⤷ Start Trial
|
